Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 38,420 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 2,820 · Balance 39,737 Row 2 · 2023-03-01 · Sale · Disposed 1,317 · Balance 38,420 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 11,017 |
Reported balance
Holding disclosure · report date 2023-02-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 11,017 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 3, 2023 00:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,317 | $100.70 | $132,621.90 |
DisclosureSEC source: 0001415889-23-003886 · form4-03032023_120331.xml · nonDerivative · entry 2 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,420 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,820 | $99.77 | $281,351.40 |
DisclosureSEC source: 0001415889-23-003886 · form4-03032023_120331.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,737 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 37,483 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003044 · form4-02222023_110235.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,483 Underlying: Common Shares · 37,483 shares Expires 2033-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,494 on February 17, 2024, 12,494 on February 17, 2025, and 12,495 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003044 · form4-02222023_110235.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,557 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 21:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 221 | $96.76 | $21,383.96 |
DisclosureSEC source: 0001415889-22-010270 · form4-10042022_021021.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,053 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,099 | $118.15 | $129,847.18 |
DisclosureSEC source: 0001415889-22-002184 · form4-03022022_040314.xml · nonDerivative · entry 2 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,274 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,561 | $122.41 | $313,492.01 |
DisclosureSEC source: 0001415889-22-002184 · form4-03022022_040314.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,373 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 54,280 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001728 · form4-02232022_040210.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,280 Underlying: Common Shares · 54,280 shares Expires 2032-02-17 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 18,093 on February 18, 2023, 18,093 on February 18, 2024, and 18,094 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 00:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,647 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001728 · form4-02232022_040210.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,934 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 30,935 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · derivative · entry 7 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,468 Underlying: Common Shares · 30,935 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,000 | $0.00 Strike: $48.98 | $0.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · derivative · entry 6 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,000 shares Expires 2027-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 21,568 | $130.00 | $2,803,840.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 4 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,287 Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 30,935 | $59.94 | $1,854,243.90 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,905 | $130.00 | $507,650.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 2 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,920 Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,000 | $48.98 | $293,880.00 |
DisclosureSEC source: 0001415889-21-005270 · form4-11172021_031105.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 220 | $118.13 | $25,988.60 |
DisclosureSEC source: 0001415889-21-004754 · form4-10052021_021021.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,825 Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,052 | $120.61 | $126,881.72 |
DisclosureSEC source: 0001415889-21-001194 · form4-03022021_030352.xml · nonDerivative · entry 2 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,045 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 23:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,282 | $121.58 | $277,445.56 |
DisclosureSEC source: 0001415889-21-001194 · form4-03022021_030352.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,097 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 47,993 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000882 · form4-02232021_020209.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Underlying: Common Shares · 47,993 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,997 on February 19, 2022, 15,998 on February 19, 2023, and 15,998 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 9,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000882 · form4-02232021_020209.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,379 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 9,084 | $0.00 Strike: $109.36 | $0.00 |
DisclosureSEC source: 0001179110-20-010243 · edgar.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,084 Underlying: Common Shares · 9,084 shares Expires 2030-09-30 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,028 on each of October 1, 2021, October 1, 2022 and October 1, 2023. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-010243 · edgar.xml · nonDerivative · entry 1 Ahlberg Gregory A · CIK 0001826317 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.